Surpass Flow Diverter for Intracranial Aneurysms: SURMOUNT Registry Data Collection
Launched by STRYKER NEUROVASCULAR · Oct 31, 2014
Trial Information
Current as of June 04, 2025
Terminated
Keywords
ClinConnect Summary
This will be a prospective, observational, multi-center, single-arm, post-marketing, international registry with consecutive enrollment of a minimum of 150 patients treated with the Surpass Flow Diverter in accordance with the standard of care at up to 30 registry sites.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who are to be treated with a Surpass Flow Diverter(s) will be eligible to participate in this registry. Patients will be enrolled on a consecutive basis.
- Exclusion Criteria:
- • This is a standard of care registry. Patients should be excluded if standard of care at a given site is such that they are not eligible for treatment with a Surpass Flow Diverter(s).
About Stryker Neurovascular
Stryker Neurovascular is a leading medical technology company focused on developing innovative solutions for the treatment of neurovascular conditions. As a subsidiary of Stryker Corporation, it specializes in advanced products and therapies aimed at improving patient outcomes in the fields of stroke intervention and surgical treatment of neurovascular diseases. With a commitment to research and development, Stryker Neurovascular works collaboratively with healthcare professionals to deliver cutting-edge technologies that enhance procedural efficiency and safety, ultimately striving to transform the standard of care in neurovascular medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Santander, , Spain
Genova, , Italy
Kortrijk, , Belgium
Kassel, , Germany
Birmingham, , United Kingdom
Mannheim, , Germany
Besançon, , France
Nijmegen, Gelderland, Netherlands
Helsinki, , Finland
Turku, , Finland
Le Kremlin Bicêtre, , France
Paris, , France
Tours, , France
Freiburg, , Germany
Treviso, , Italy
Stockholm, , Sweden
Romford, Essex, United Kingdom
Liverpool, , United Kingdom
Patients applied
Trial Officials
Patrick A Brouwer, MD
Principal Investigator
Karolinska Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials